Navigation Links
Chimerix's PIM Conjugate Technology Reduces Risk of Nephrotoxicity for CMX001 and CMX157
Date:11/16/2010

rganic Anion Transporter 1 (hOAT1) and hOAT3, which are both linked to kidney excretion of endogenous substances and certain drugs.  Researchers noted that net uptake of CMX001 and CMX157 was not enhanced in OAT-expressing cells.  These data provide evidence that CMX001 and CMX157 are not substrates of human OAT1 and OAT3 and therefore have a low potential to cause OAT-mediated nephrotoxicity.  In contrast, uptake of cidofovir and tenofovir was enhanced in in vitro cells expressing OAT1, consistent with previous literature reports.  

"Nephrotoxicity is a serious and potentially life-threatening adverse effect associated with the antiviral agents cidofovir and tenofovir.  Through the application of our proprietary PIM Conjugate Technology we are able to dramatically alter drug distribution and thereby potentially avoid nephrotoxicity," said George Painter, Ph.D., Chief Scientific Officer of Chimerix.  "Our animal and clinical studies of CMX001 and CMX157, in which both compounds have demonstrated a positive safety profile, are consistent with our in vitro observations that CMX001 and CMX157 are not metabolized in the kidney.  Furthermore, these data are consistent with, and provide a mechanistic explanation for, data presented at the recent ICAAC meeting that CMX001 was well tolerated in 46 patients with compromised renal function."

Chimerix is developing CMX001 for dual-use as a broad-spectrum antiviral for the treatment of life-threatening viruses in immunocompromised transplant and cancer patients and as a medical countermeasure in the event of a smallpox release.  CMX001 is currently in Phase 2 clinical trials for the prophylaxis and treatment of human cytomegalovirus infection. CMX157 is currently in Phase 1 clinical testing for the treatment of HIV infections.

Cidofovir and tenofovir are polar, acyclic nucleoside phosphonates that are FDA-approved as Vistide® (cidofovir injection) f
'/>"/>

SOURCE Chimerix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Aeterna Zentaris: FDA Approves Investigational New Drug (IND) Application for Doxorubicin Targeted Conjugate Compound, AEZS-108, in Bladder Cancer
2. AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer
3. Medarex Announces Allowance of Investigational New Drug Application for Companys First Antibody-Drug Conjugate, MDX-1203
4. AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Endometrial Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108
5. Retrospective Analysis of Phase 3 Data Suggest Wyeths Investigational Compound Bazedoxifene/Conjugated Estrogens Comparable to Placebo on Incidence of Abnormal Mammograms
6. Cyprus and Ireland Add Wyeths 7-Valent Pneumococcal Conjugate Vaccine (PCV7) to Their National Immunisation Schedules
7. The Israeli Governments Ministry of Health Invites Medisafe 1 Technologies to Demonstrate its Unique Syringe Locking Device Technology
8. Oramed Pharmaceuticals Presents Results of its Phase IIb Clinical Trial at the Diabetes Technology Meeting 2010 in Bethesda, MD
9. New forms of highly efficient, flexible nanogenerator technology
10. Verenium to Present at Jefferies 10th Global Clean Technology Conference
11. Voluntary initiatives, regulation and nanotechnology oversight
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 AudioNotch is the internet's leading ... the treatment of tinnitus. Patients listen to sound therapy ... a period of weeks to months, their tinnitus volume decreases. ... forms: Notched Music and Notched White Noise. Now, AudioNotch is ...
(Date:1/14/2014)... 2014 Carahsoft and CDS Federal Services ... 2014 at 2pm EST (11am PST), “Natural Language Processing: ... on how technology can turn raw, heterogeneous data into ... agencies. The online webinar will last approximately one hour. ...
(Date:1/14/2014)... Jan. 14, 2014 As pet owners drew up their lists ... them wrote: "Take better care of my furry companion." Nowadays there ... and top-brand carrying cases to take the little canine or feline ... feel compelled to buy some pricey toys at the pet store. ...
(Date:1/14/2014)... BETHESDA, Md. , Jan. 14, 2014  Organovo ... institutes from the National Institutes of Health (NIH) to ... more effective treatments to patients on a faster timeline. ... Translational Sciences (NCATS) and the National Eye Institute (NEI) ...
Breaking Biology Technology:Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3
... Limited-English Interpretation, TUCSON, Ariz., Sept. 26 ... limited-English speaking patients in,hospitals and health care ... of the industry,s first dual-handset cordless phone,ClearLink(TM) ... of its patented,dual-handset phone now known as ...
... Trials and Commercialization, PALO ALTO, Calif., Sept. ... a late-stage biotechnology company that,develops central nervous system ... conducted an initial closing of its,private offering of ... gross proceeds of $3,110,000 and in exchange sold,3,110 ...
... BV, a world leader in,the rapidly evolving field of ... Personalized Medicine Coalition (PMC). "The PMC is playing ... on,personalized medicine. We are very pleased to be a ... of patients in the future. After we,got both our ...
Cached Biology Technology:Industry-First Telephone for Health Care Developed by CyraCom 2Avicena Group Announces Closing of Private Offering 2Agendia Joins the Personalized Medicine Coalition (PMC) 2
(Date:4/17/2014)... German . Our ... provide us with a continuous stream of information about our ... still in a car the world glides by us ... without effort, our brain calculates self-motion from this "optic flow". ... steady gaze during our own movements. Together with biologists from ...
(Date:4/17/2014)... German . If ... of him, he can expect his premises to be trashed. ... the consequences is enough to make restaurant owners pay up. ... their eggs in other birds, nests. If the host birds ... revenge by destroying the entire nest. Consequently, it is beneficial ...
(Date:4/17/2014)... painted a stark warning on the possible effects of ... effect 32 times that of carbon dioxide. Now a ... act as fully regenerable electron acceptors which helps explain ... instead of being released to the atmosphere. However, there ... may enter into a vicious cycle to release large ...
Breaking Biology News(10 mins):How vision makes sure that little fish do not get carried away 2How vision makes sure that little fish do not get carried away 3How vision makes sure that little fish do not get carried away 4Fear of the cuckoo mafia 2Fear of the cuckoo mafia 3Methane climate change risk suggested by proof of redox cycling of humic substances 2
... fever destroys the small farmer's dream of escaping poverty in ... $200 million annually, this tick-borne disease rages across a dozen ... of scientists has taken the first major step toward a ... the February 13-17 early online edition of the Proceedings ...
... quarter century after they discovered it, researchers have identified ... response proteins. The enzyme has puzzled scientists because ... that it is crucial to life, and yet, in ... , The discovery suggests that the enigmatic enzyme known ...
... (miRNAs) that appear to play a significant role in ... body's ability to form clots following an injury. They ... abnormally, may contribute to certain forms of leukemia. , ... genes are turned off in normal platelet development, but ...
Cached Biology News:Genomics-based vaccine could prevent deadly cattle disease 2Genomics-based vaccine could prevent deadly cattle disease 3Common enzyme is a key player in DNA repair 2Common enzyme is a key player in DNA repair 3MiRNA fingerprint identified in platelet formation 2